JP2017503488A5 - - Google Patents

Download PDF

Info

Publication number
JP2017503488A5
JP2017503488A5 JP2016541175A JP2016541175A JP2017503488A5 JP 2017503488 A5 JP2017503488 A5 JP 2017503488A5 JP 2016541175 A JP2016541175 A JP 2016541175A JP 2016541175 A JP2016541175 A JP 2016541175A JP 2017503488 A5 JP2017503488 A5 JP 2017503488A5
Authority
JP
Japan
Prior art keywords
marker gene
group
ctc
expression product
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016541175A
Other languages
English (en)
Japanese (ja)
Other versions
JP6599334B2 (ja
JP2017503488A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/071169 external-priority patent/WO2015095527A1/en
Publication of JP2017503488A publication Critical patent/JP2017503488A/ja
Publication of JP2017503488A5 publication Critical patent/JP2017503488A5/ja
Priority to JP2019181785A priority Critical patent/JP6912538B2/ja
Application granted granted Critical
Publication of JP6599334B2 publication Critical patent/JP6599334B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016541175A 2013-12-20 2014-12-18 血中循環腫瘍細胞に関する方法およびアッセイ Active JP6599334B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019181785A JP6912538B2 (ja) 2013-12-20 2019-10-02 血中循環腫瘍細胞に関する方法およびアッセイ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361918816P 2013-12-20 2013-12-20
US61/918,816 2013-12-20
US201461937883P 2014-02-10 2014-02-10
US61/937,883 2014-02-10
PCT/US2014/071169 WO2015095527A1 (en) 2013-12-20 2014-12-18 Methods and assays relating to circulating tumor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019181785A Division JP6912538B2 (ja) 2013-12-20 2019-10-02 血中循環腫瘍細胞に関する方法およびアッセイ

Publications (3)

Publication Number Publication Date
JP2017503488A JP2017503488A (ja) 2017-02-02
JP2017503488A5 true JP2017503488A5 (cg-RX-API-DMAC7.html) 2018-03-08
JP6599334B2 JP6599334B2 (ja) 2019-10-30

Family

ID=53403695

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016541175A Active JP6599334B2 (ja) 2013-12-20 2014-12-18 血中循環腫瘍細胞に関する方法およびアッセイ
JP2019181785A Active JP6912538B2 (ja) 2013-12-20 2019-10-02 血中循環腫瘍細胞に関する方法およびアッセイ
JP2021113478A Active JP7330235B2 (ja) 2013-12-20 2021-07-08 血中循環腫瘍細胞に関する方法およびアッセイ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019181785A Active JP6912538B2 (ja) 2013-12-20 2019-10-02 血中循環腫瘍細胞に関する方法およびアッセイ
JP2021113478A Active JP7330235B2 (ja) 2013-12-20 2021-07-08 血中循環腫瘍細胞に関する方法およびアッセイ

Country Status (7)

Country Link
US (2) US10900083B2 (cg-RX-API-DMAC7.html)
EP (2) EP3082840B1 (cg-RX-API-DMAC7.html)
JP (3) JP6599334B2 (cg-RX-API-DMAC7.html)
CN (2) CN106456694B (cg-RX-API-DMAC7.html)
AU (2) AU2014364520B2 (cg-RX-API-DMAC7.html)
CA (1) CA2934344A1 (cg-RX-API-DMAC7.html)
WO (1) WO2015095527A1 (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6599334B2 (ja) * 2013-12-20 2019-10-30 ザ ジェネラル ホスピタル コーポレイション 血中循環腫瘍細胞に関する方法およびアッセイ
WO2017181135A2 (en) 2016-04-15 2017-10-19 Berkeley Lights, Inc. Methods, systems and kits for in-pen assays
CA3032528A1 (en) 2016-09-15 2018-03-22 Augmenta Bioworks, Inc. Immune repertoire sequence amplification methods and applications
WO2018064284A1 (en) 2016-09-30 2018-04-05 Novaflux, Inc. Compositions for cleaning and decontamination
WO2018084836A1 (en) * 2016-11-02 2018-05-11 Development Center For Biotechnology Anti-tmcc3 immunoconjugates and uses thereof
IL269315B2 (en) * 2017-03-16 2025-05-01 Univ Bruxelles Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker
CN106939340A (zh) * 2017-03-31 2017-07-11 哈尔滨医科大学 一种与肺腺癌转移及预后相关的分子标记物及其应用
CN109554450A (zh) * 2017-09-25 2019-04-02 上海艾壳基因技术有限公司 循环肿瘤细胞捕获并进行全基因转录组检测的方法
WO2019075476A2 (en) 2017-10-15 2019-04-18 Berkeley Lights, Inc. METHODS, SYSTEMS AND KITS FOR ENCLOSED TESTS
CN109988825B (zh) * 2017-12-29 2023-03-10 杭州莲和医学检验所有限公司 构建细胞全转录本扩增产物的方法及其应用
AU2019207535B2 (en) * 2018-01-15 2021-12-23 Epiaxis Therapeutics Pty Ltd Agents and methods for predicting response to therapy
US11345878B2 (en) * 2018-04-03 2022-05-31 Novaflux Inc. Cleaning composition with superabsorbent polymer
WO2020047170A1 (en) * 2018-08-28 2020-03-05 Duke University Biomarkers, compositions, and methods for diagnosing and treating subjects exposed to protein/heparin complexes
WO2020055954A2 (en) * 2018-09-11 2020-03-19 The General Hospital Corporation Methods for detecting liver diseases
WO2020077017A2 (en) * 2018-10-10 2020-04-16 Augmenta Bioworks, Inc. Methods for isolating immune binding proteins
CN109266714A (zh) * 2018-10-12 2019-01-25 广州医科大学 一种循环肿瘤细胞的检测方法
TWI734242B (zh) * 2018-11-01 2021-07-21 中央研究院 轉移癌之治療及預後
CN109439732B (zh) * 2018-12-25 2024-04-12 迈迪速能医学技术(天津)有限公司 一种用于三维无创肿瘤早筛的试剂盒
CN113785050B (zh) * 2019-04-30 2025-03-14 加利福尼亚大学董事会 使用广谱纳米颗粒实现基因组检测
CN110229903A (zh) * 2019-06-25 2019-09-13 台州市立医院 Podn作为诊断甲状腺癌的分子标志物
KR102699848B1 (ko) * 2019-07-29 2024-08-29 서울대학교병원 암 진단을 위한 바이오마커
EP4041180A1 (en) 2019-10-03 2022-08-17 Novaflux Inc. Oral cavity cleaning composition, method, and apparatus
US12064495B2 (en) 2019-10-03 2024-08-20 Protegera, Inc. Oral cavity cleaning composition, method, and apparatus
JP7475626B2 (ja) * 2019-11-01 2024-04-30 学校法人近畿大学 バイオマーカーを用いた哺乳動物胚の選別方法
CN111073980B (zh) * 2020-01-02 2020-10-27 牡丹江医学院 一种肝内胆管细胞癌的诊断方法及诊断试剂盒
CN114058699B (zh) * 2020-07-31 2023-04-07 中国科学院上海营养与健康研究所 Ppdpf在胰腺癌诊断及药物制备中的应用
JP7477872B2 (ja) * 2020-09-30 2024-05-07 国立大学法人大阪大学 癌に関連する新規バイオマーカー
CN112992266B (zh) * 2021-02-05 2021-09-21 深圳裕康医学检验实验室 一种评估肿瘤免疫耗竭状态的方法、装置和存储介质
CN112852816B (zh) * 2021-02-25 2023-03-31 中国医科大学附属盛京医院 一种针对dnajb11基因的靶向抑制剂及其应用
JP7732839B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
JP7732841B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
JP7732840B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
JP7732843B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
JP7732842B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
CN114875135B (zh) * 2021-12-25 2023-01-10 济宁医学院 Ogn基因作为生物标志物在制备诊断胰腺癌的试剂盒中的应用
CN114317747A (zh) * 2021-12-28 2022-04-12 深圳市人民医院 Swi5在结肠癌的预后中的应用
CN114317775B (zh) * 2022-01-12 2023-06-30 中国人民解放军军事科学院军事医学研究院 一种NCOA4的RNA m6A修饰作为γ射线辐射标志物的应用
US20250195555A1 (en) * 2022-03-16 2025-06-19 Empirico Inc. Treatment of hgfac related diseases and disorders
CN115058516A (zh) * 2022-04-28 2022-09-16 北京大学第三医院(北京大学第三临床医学院) 用于上皮性卵巢癌诊断的标志物及其应用
CN114940714B (zh) * 2022-05-20 2023-06-16 湖南师范大学 肝癌标志物soat1单克隆抗体制备及其应用
CN115927642B (zh) * 2023-01-21 2024-08-13 四川大学华西医院 Rgs18在治疗肿瘤转移中的应用
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
CN116577506A (zh) * 2023-04-26 2023-08-11 苏州大学 一种鉴别hcc亚型的标志物hnf1b及dphcc体外模型的构建
CN116694756A (zh) * 2023-06-28 2023-09-05 复旦大学附属华山医院 家族性成人肌阵挛癫痫的诊断标志物和应用
WO2025059345A1 (en) * 2023-09-14 2025-03-20 Empirico Inc. Treatment of hgfac related diseases and disorders
CN118858637B (zh) * 2024-09-26 2024-12-17 四川大学华西医院 一种用于捕获循环肿瘤细胞的标志物组及试剂盒与装置

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4135884A (en) 1977-08-29 1979-01-23 Shen James T Gamma stick
US4305924A (en) 1979-08-08 1981-12-15 Ventrex Laboratories, Inc. Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US4444880A (en) 1982-07-27 1984-04-24 Syva Company Periodate removal of ascorbate interference in dipsticks for immunoassays
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
EP0560410B1 (en) 1987-04-27 2002-10-02 Inverness Medical Switzerland GmbH A test device for performing specific binding assays
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
JP2828642B2 (ja) 1987-06-24 1998-11-25 ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン ヌクレオシド誘導体
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
JPH03503894A (ja) 1988-03-25 1991-08-29 ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション オリゴヌクレオチド n‐アルキルホスホラミデート
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
JPH05504552A (ja) 1989-10-24 1993-07-15 ギリアド サイエンシズ,インコーポレイテッド 2’位が改変されたオリゴヌクレオチド
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
CA2029273A1 (en) 1989-12-04 1991-06-05 Christine L. Brakel Modified nucleotide compounds
US5852188A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DK0455905T3 (da) 1990-05-11 1998-12-07 Microprobe Corp Dipsticks til nukleinsyrehybridiseringsassays og fremgangsmåde til kovalent immobilisering af oligonukleotider
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5614617A (en) 1990-07-27 1997-03-25 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
IL113519A (en) 1990-08-03 1997-11-20 Sterling Winthrop Inc Oligonucleoside sequences of from about 6 to about 200 bases having a three atom internucleoside linkage, their preparation and pharmaceutical compositions for inhibiting gene expression containing said oligonucleosides
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
AU662298B2 (en) 1990-09-20 1995-08-31 Gilead Sciences, Inc. Modified internucleoside linkages
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
GB9100304D0 (en) 1991-01-08 1991-02-20 Ici Plc Compound
WO1992012428A1 (en) 1991-01-11 1992-07-23 Quidel Corporation A one-step lateral flow nonbibulous assay
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
ES2103918T3 (es) 1991-10-17 1997-10-01 Ciba Geigy Ag Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
EP0618925B2 (en) 1991-12-24 2012-04-18 Isis Pharmaceuticals, Inc. Antisense oligonucleotides
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US6277603B1 (en) 1991-12-24 2001-08-21 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
DE4203923A1 (de) 1992-02-11 1993-08-12 Henkel Kgaa Verfahren zur herstellung von polycarboxylaten auf polysaccharid-basis
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
DK0691968T3 (da) 1993-03-30 1998-02-23 Sanofi Sa Acykliske nukleosid-analoge og oligonukleotidsekvenser indeholdende disse
WO1994022891A1 (en) 1993-03-31 1994-10-13 Sterling Winthrop Inc. Oligonucleotides with amide linkages replacing phosphodiester linkages
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US5955591A (en) 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
IL111659A0 (en) 1993-11-16 1995-01-24 Genta Inc Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US6608035B1 (en) 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6444423B1 (en) 1996-06-07 2002-09-03 Molecular Dynamics, Inc. Nucleosides comprising polydentate ligands
US6639062B2 (en) 1997-02-14 2003-10-28 Isis Pharmaceuticals, Inc. Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6524681B1 (en) 1997-04-08 2003-02-25 3M Innovative Properties Company Patterned surface friction materials, clutch plate members and methods of making and using same
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6528640B1 (en) 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US7273933B1 (en) 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US7045610B2 (en) 1998-04-03 2006-05-16 Epoch Biosciences, Inc. Modified oligonucleotides for mismatch discrimination
US6531590B1 (en) 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6867289B1 (en) 1998-10-26 2005-03-15 Board Of Regents, The University Of Texas Systems Thio-modified aptamer synthetic methods and compositions
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
CN102180924A (zh) 1999-05-04 2011-09-14 桑塔里斯制药公司 L-核糖-lna类似物
US6593466B1 (en) 1999-07-07 2003-07-15 Isis Pharmaceuticals, Inc. Guanidinium functionalized nucleotides and precursors thereof
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
JP4267233B2 (ja) 1999-09-10 2009-05-27 ジェロン・コーポレーション オリゴヌクレオチドn3’→p5’チオホスホルアミデート:それらの合成および使用
US7321029B2 (en) 2000-01-21 2008-01-22 Geron Corporation 2′-arabino-fluorooligonucleotide N3′→P5′ phosphoramidates: their synthesis and use
AU2001293687A1 (en) 2000-10-04 2002-04-15 Cureon A/S Improved synthesis of purine locked nucleic acid analogues
US6565808B2 (en) 2001-05-18 2003-05-20 Acon Laboratories Line test device and methods of use
AUPR633101A0 (en) * 2001-07-13 2001-08-02 University Of Sydney, The Method
US6902932B2 (en) 2001-11-16 2005-06-07 Tissue Regeneration, Inc. Helically organized silk fibroin fiber bundles for matrices in tissue engineering
US20110009960A1 (en) 2001-11-16 2011-01-13 Allergan, Inc. Prosthetic fabric structure
US6878805B2 (en) 2002-08-16 2005-04-12 Isis Pharmaceuticals, Inc. Peptide-conjugated oligomeric compounds
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2004079012A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein tyrosine phosphatase-prl-1 a a marker and therapeutic target for pancreatic cancer
US7427672B2 (en) 2003-08-28 2008-09-23 Takeshi Imanishi Artificial nucleic acids of n-o bond crosslinkage type
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US9416422B2 (en) * 2005-02-18 2016-08-16 Sloan-Kettering Institute For Cancer Research Methods for detecting minimum residual disease
ITVI20050059A1 (it) * 2005-03-04 2006-09-05 Consorzio Per Gli Studi Universitari In Verona Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali
US20070104717A1 (en) * 2005-09-12 2007-05-10 Regents Of The University Of Michigan Compositions and methods for detecting and treating cancer
CN102908630B (zh) 2006-01-27 2014-11-19 Isis制药公司 6-修饰的双环核酸类似物
WO2007089911A2 (en) * 2006-01-30 2007-08-09 The Scripps Research Institute Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
WO2008061091A2 (en) 2006-11-13 2008-05-22 Grandis Jennifer R Antisense guanidinium peptide nucleic acid (gpna) oligonucleotides as antitumor agents
EP2139430B1 (en) 2007-03-20 2019-06-05 Serica Technologies, Inc. Tendon prosthesis and method of manufacturing the same
WO2009051734A1 (en) * 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
EP2245055A2 (en) * 2008-01-31 2010-11-03 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
KR101970908B1 (ko) * 2008-02-01 2019-04-19 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
EP2335075A4 (en) * 2008-09-05 2011-12-14 Scripps Research Inst METHOD FOR DETECTING CIRCULATING TUMOR CELLS
WO2010027512A2 (en) 2008-09-06 2010-03-11 Chemgenes Corporation Rna synthesis - phosphoramidites for synthetic rna in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic rna at the 3' - end
US20110020221A1 (en) * 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
WO2011112903A2 (en) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
US20110256155A1 (en) * 2010-04-16 2011-10-20 Medimmune, Llc Methods to molecularly characterize circulating tumor cells
BR112013000433A2 (pt) * 2010-07-07 2016-05-17 Univ Michigan diagnóstico e tratamento de câncer de mama
WO2012012801A2 (en) * 2010-07-23 2012-01-26 The Johns Hopkins University Device for capture, enumeration, and profiling of circulating tumor cells
CN103782174A (zh) * 2011-06-07 2014-05-07 卡里斯生命科学卢森堡控股有限责任公司 用于癌症的循环生物标志物
US20130035630A1 (en) * 2011-08-04 2013-02-07 IVDiagnostics, LLC Aptamer for the Capture, Diagnosis, Enumeration, and Eradication of Circulating Tumor Cells
WO2013109944A1 (en) * 2012-01-18 2013-07-25 The Trustees Of The University Of Pennsylvania Methods for assessing risk for cancer using biomarkers
CN104136041B (zh) * 2012-02-09 2021-06-29 Var2制药有限公司 靶向硫酸软骨素聚糖
WO2013134649A1 (en) * 2012-03-09 2013-09-12 Verastem, Inc. Biomarkers for cancer stem cells and related methods of use
JP6599334B2 (ja) * 2013-12-20 2019-10-30 ザ ジェネラル ホスピタル コーポレイション 血中循環腫瘍細胞に関する方法およびアッセイ
WO2015191491A1 (en) 2014-06-09 2015-12-17 The Procter & Gamble Company Flushing dispensers for delivering a consistent consumer experience
TW201923089A (zh) * 2017-11-06 2019-06-16 美商建南德克公司 癌症之診斷及治療方法

Similar Documents

Publication Publication Date Title
JP2017503488A5 (cg-RX-API-DMAC7.html)
Wang et al. c‐Myc‐mediated epigenetic silencing of MicroRNA‐101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma
Wang et al. Atherosclerosis-related circulating miRNAs as novel and sensitive predictors for acute myocardial infarction
US10744116B2 (en) Detection and treatment of anti-PD-1 therapy resistant metastatic melanomas
Chan et al. MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis
Huang et al. Overexpression of long noncoding RNA HOTAIR predicts a poor prognosis in patients with cervical cancer
Ma et al. Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2–M transition genes
Zhang et al. Long noncoding RNA SNHG15, a potential prognostic biomarker for hepatocellular carcinoma
Thanee et al. Quantitative changes in tumor-associated M2 macrophages characterize cholangiocarcinoma and their association with metastasis
US20230146253A1 (en) Methods related to bronchial premalignant lesion severity and progression
JP7390285B2 (ja) 老化細胞を検出するための新規バイオマーカー
JP2017507320A5 (cg-RX-API-DMAC7.html)
JP7463351B2 (ja) 脳卒中の血液バイオマーカー
JP5837825B2 (ja) 線維症感受性遺伝子及びその使用
Wei et al. Long non-coding RNA ZEB1-AS1 promotes glioma cell proliferation, migration and invasion through regulating miR-577.
JP2018527886A5 (cg-RX-API-DMAC7.html)
WO2020148589A1 (en) Early biomarkers for cardiac patients
Wang et al. Classic SRY‐box protein SOX7 functions as a tumor suppressor regulating WNT signaling and is methylated in renal cell carcinoma
CN110055327A (zh) 用于预测癌症免疫治疗效果的内皮细胞标记物与试剂盒
Shi et al. The impact of sphingosine kinase 1 on the prognosis of hepatocellular carcinoma patients with portal vein tumor thrombus
Zhang et al. Genetic variation of ITGB3 is associated with asthma in Chinese Han children
Xu et al. GATA6-AS1 inhibits ovarian cancer cell proliferation and migratory and invasive abilities by sponging miR-19a-5p and upregulating TET2
CN111315897B (zh) 用于黑素瘤检测的方法
Kong et al. Overexpression of activating transcription factor 5 in human rectal cancer
AU2020357978A1 (en) Methods for determining responsiveness to anti-tumor necrosis factor therapy in the treatment of psoriasis